Kyowa Kirin Announces Board Approval for Construction of New Biologics Manufacturing Plant in Sanford, NC

A key driver of the new manufacturing facility is the growing global imperative to treat diseases that individually are rare, but which collectively affect an estimated 263 to 446 million people worldwide.1 Kyowa Kirin is uniquely positioned to fulfill the unmet needs of patients living with rare and underserved diseases by continuing to build on its more than 70-year history of discovering and developing novel medicines that offer life-changing value to patients. The Sanford facility will round out and enh ...